Aboagye E O, Lewis A D, Johnson A, Workman P, Tracy M, Huxham I M
CRC Department of Medical Oncology, University of Glasgow, Beatson Laboratories, UK.
Br J Cancer. 1995 Aug;72(2):312-8. doi: 10.1038/bjc.1995.330.
The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160 microns from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively retained in the cells in which they are metabolised through covalent association with subcellular components. These findings provide additional support for the clinical development of the drug as a non-invasive probe for tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the heterogeneity of drug distribution both between and within cells.
新型氟化2-硝基咪唑SR-4554正在进行临床前开发,作为一种用于缺氧肿瘤细胞的磁共振波谱和成像探针。我们使用电子能量损失光谱分析(EELS)来显示SR-4554在人卵巢多细胞球体中的选择性还原和亚细胞定位差异。已证明SR-4554在缺氧但非正常需氧细胞培养条件下可被这些A2780细胞代谢。EELS技术表明,在与药物初始孵育3小时后,球体内部区域(距边缘150 - 160微米)和外边缘细胞胞质内的药物相对量没有显著差异。相比之下,在随后于无药培养基中进行2小时“追踪”培养后,观察到球体内部与外部区域细胞胞质(主要是核糖体和内质网)中保留的药物量存在8倍差异。在球体缺氧区域的细胞内,SR-4554主要与内质网、细胞核以及细胞内囊泡的胞质侧相关,在较小程度上也与核周相关。有趣的是,该药物仅与细胞的线粒体和质膜有较弱的关联。SR-4554的细胞和亚细胞分布特征与2-硝基咪唑化合物经缺氧介导的酶促还原为活性物质的假设一致。这些活性物质通过与亚细胞成分的共价结合而选择性地保留在它们被代谢的细胞中。这些发现为该药物作为肿瘤缺氧的非侵入性探针的临床开发提供了额外支持,同时也说明了EELS技术在检查细胞间和细胞内药物分布异质性方面的实用性。